QH103 / Anhui Provincial Hospital, Beijing Qinghui Liannuo Biotechnology - LARVOL DELTA

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases (clinicaltrials.gov) - P1/2 | N=9 | Recruiting | Sponsor: Peking University Third Hospital | Not yet recruiting ➔ Recruiting | Initiation date: Feb 2025 ➔ Jul 2025

Enrollment open • Trial initiation date • ANCA Vasculitis • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Myositis • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases (clinicaltrials.gov) - P1/2 | N=9 | Not yet recruiting | Sponsor: Peking University Third Hospital

New P1/2 trial • ANCA Vasculitis • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Myositis • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis

An open-label clinical study to evaluate the safety and pharmacodynamics of QH103 cell injection (CD19 CAR-γδT cells) in the treatment of relapsed/refractory autoimmune diseases (ChiCTR) - P=N/A | N=18 | Sponsor: Bejing GoBroad Hospital; Bejing GoBroad Hospital

New trial • Immunology • CD19

QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Anhui Provincial Hospital

New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • IL10 • IL2 • IL6 • TNFA